Researchers at Tokyo University of Agriculture and Technology described in Bioscience, Biotechnology, and Biochemistry, published online Monday, October 5, 2026, a liquid-phase peptide synthesis method that pulls tagged peptides out of solution with hydrophobic magnetic nanoparticles after each coupling and deprotection step, replacing the slow filtration step of conventional tag-assisted synthesis. Liquid-phase synthesis uses fewer reagents and solvents than the standard solid-phase method. The team made the model peptide leucine-enkephalin in high yield and purity without chromatography; the abstract reports results only for that model peptide.
SNS Insider published its 2026 Peptide Synthesis Market Report on Tuesday May 19, projecting the global peptide synthesis market to reach $1,889.88M by 2035 from current levels, anchored on GLP-1 receptor agonist demand and the broader peptide therapeutics pipeline. The report tracks the major SPPS capacity expansions: CordenPharma's $500M+ Boulder Colorado site adding 25,000L+ to reach 42,000L total by 2028, Bachem's three-site expansion (Bubendorf Switzerland, St Helens UK, Vista California) plus a new Sisseln Switzerland facility, and PolyPeptide's €200M credit facility supporting the doubling of 2023 revenue by 2028. The structural read: incretin-class peptide demand (semaglutide, tirzepatide, retatrutide, mazdutide, survodutide, eleglipron) plus the next-generation pipeline (NK2R agonists, amylin combos, peptide-drug conjugates) is the demand wave the CDMOs are positioning against.